AIFM1
Basic information
Region (hg38): X:130124666-130165879
Previous symbols: [ "PDCD8", "NAMSD", "AUNX1" ]
Links
Phenotypes
GenCC
Source:
- X-linked hereditary sensory and autonomic neuropathy with hearing loss (Strong), mode of inheritance: XL
- severe X-linked mitochondrial encephalomyopathy (Strong), mode of inheritance: XLR
- spondyloepimetaphyseal dysplasia, Bieganski type (Supportive), mode of inheritance: XL
- Charcot-Marie-Tooth disease X-linked recessive 4 (Supportive), mode of inheritance: XL
- X-linked hereditary sensory and autonomic neuropathy with hearing loss (Supportive), mode of inheritance: XL
- severe X-linked mitochondrial encephalomyopathy (Supportive), mode of inheritance: XL
- severe X-linked mitochondrial encephalomyopathy (Strong), mode of inheritance: XL
- X-linked hereditary sensory and autonomic neuropathy with hearing loss (Strong), mode of inheritance: XL
- severe X-linked mitochondrial encephalomyopathy (Strong), mode of inheritance: XL
- spondyloepimetaphyseal dysplasia, Bieganski type (Strong), mode of inheritance: XL
- Charcot-Marie-Tooth disease X-linked recessive 4 (Strong), mode of inheritance: XL
- X-linked hereditary sensory and autonomic neuropathy with hearing loss (Definitive), mode of inheritance: XL
- Leigh syndrome (Moderate), mode of inheritance: XL
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Deafness, X-linked 5 | XL | Audiologic/Otolaryngologic | Early recognition and treatment of hearing impairment may improve outcomes, including speech and language development | Audiologic/Otolaryngologic; Biochemical; Cardiovascular; Musculoskeletal; Neurologic | 16816020; 20362274; 22019070; 23217327; 25986071; 27102849; 28842795 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the AIFM1 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 79 | 85 | ||||
missense | 18 | 152 | 23 | 194 | ||
nonsense | 0 | |||||
start loss | 1 | |||||
frameshift | 0 | |||||
inframe indel | 4 | |||||
splice donor/acceptor (+/-2bp) | 0 | |||||
splice region | 14 | 15 | 1 | 30 | ||
non coding | 84 | 17 | 110 | |||
Total | 0 | 19 | 167 | 186 | 22 |
Variants in AIFM1
This is a list of pathogenic ClinVar variants found in the AIFM1 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
X-130129397-T-C | Likely benign (Sep 29, 2018) | |||
X-130129508-G-A | Severe X-linked mitochondrial encephalomyopathy | Uncertain significance (Jan 13, 2018) | ||
X-130129537-G-T | Charcot-Marie-Tooth disease | Likely benign (-) | ||
X-130129566-A-G | not specified • Combined oxidative phosphorylation deficiency;Charcot-Marie-Tooth Neuropathy X • Charcot-Marie-Tooth disease • Severe X-linked mitochondrial encephalomyopathy • Deafness, X-linked 5;Charcot-Marie-Tooth disease X-linked recessive 4;Severe X-linked mitochondrial encephalomyopathy;Spondyloepimetaphyseal dysplasia, Bieganski type • Inborn genetic diseases | Benign/Likely benign (Jan 31, 2024) | ||
X-130129578-T-C | Charcot-Marie-Tooth Neuropathy X;Combined oxidative phosphorylation deficiency | Likely benign (Sep 25, 2021) | ||
X-130129579-A-T | Combined oxidative phosphorylation deficiency;Charcot-Marie-Tooth Neuropathy X | Uncertain significance (Nov 22, 2022) | ||
X-130129594-T-C | Charcot-Marie-Tooth Neuropathy X;Combined oxidative phosphorylation deficiency | Uncertain significance (Mar 22, 2020) | ||
X-130129605-A-G | not specified • Combined oxidative phosphorylation deficiency;Charcot-Marie-Tooth Neuropathy X • Inborn genetic diseases | Likely benign (Oct 21, 2022) | ||
X-130129616-C-T | Combined oxidative phosphorylation deficiency;Charcot-Marie-Tooth Neuropathy X | Uncertain significance (Apr 26, 2023) | ||
X-130129617-G-A | Charcot-Marie-Tooth disease | Likely benign (-) | ||
X-130129618-T-G | Charcot-Marie-Tooth Neuropathy X;Combined oxidative phosphorylation deficiency | Uncertain significance (Sep 01, 2022) | ||
X-130129620-C-T | Charcot-Marie-Tooth Neuropathy X;Combined oxidative phosphorylation deficiency | Likely benign (Jul 31, 2022) | ||
X-130129626-G-C | Deafness, X-linked 5 | Likely pathogenic (-) | ||
X-130129636-A-G | Combined oxidative phosphorylation deficiency;Charcot-Marie-Tooth Neuropathy X | Likely benign (Apr 18, 2023) | ||
X-130129637-G-A | Likely benign (May 16, 2018) | |||
X-130129639-G-A | Charcot-Marie-Tooth Neuropathy X;Combined oxidative phosphorylation deficiency | Likely benign (Feb 18, 2023) | ||
X-130129640-A-G | Combined oxidative phosphorylation deficiency;Charcot-Marie-Tooth Neuropathy X | Likely benign (Mar 28, 2022) | ||
X-130129640-AGAGT-A | Charcot-Marie-Tooth Neuropathy X;Combined oxidative phosphorylation deficiency | Likely benign (Feb 24, 2022) | ||
X-130129641-G-A | Charcot-Marie-Tooth Neuropathy X;Combined oxidative phosphorylation deficiency | Likely benign (Jun 30, 2023) | ||
X-130129642-A-T | Combined oxidative phosphorylation deficiency;Charcot-Marie-Tooth Neuropathy X | Likely benign (Jan 14, 2023) | ||
X-130129824-C-T | Likely benign (Aug 03, 2018) | |||
X-130129958-A-G | Spondyloepimetaphyseal dysplasia, Bieganski type • Combined oxidative phosphorylation deficiency;Charcot-Marie-Tooth Neuropathy X | Conflicting classifications of pathogenicity (Nov 28, 2023) | ||
X-130129959-C-T | Charcot-Marie-Tooth Neuropathy X;Combined oxidative phosphorylation deficiency | Likely benign (Aug 04, 2023) | ||
X-130129963-C-A | Charcot-Marie-Tooth Neuropathy X;Combined oxidative phosphorylation deficiency | Likely benign (Jun 30, 2023) | ||
X-130129965-C-A | Combined oxidative phosphorylation deficiency;Charcot-Marie-Tooth Neuropathy X | Uncertain significance (Aug 24, 2021) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
AIFM1 | protein_coding | protein_coding | ENST00000287295 | 16 | 36525 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
0.998 | 0.00205 | 125711 | 0 | 2 | 125713 | 0.00000795 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | 2.49 | 130 | 238 | 0.545 | 0.0000184 | 3955 |
Missense in Polyphen | 14 | 67.99 | 0.20591 | 1088 | ||
Synonymous | 0.569 | 86 | 93.0 | 0.925 | 0.00000774 | 1231 |
Loss of Function | 4.45 | 2 | 26.9 | 0.0743 | 0.00000222 | 408 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00 | 0.00 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.00 | 0.00 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.0000122 | 0.00000879 |
Middle Eastern | 0.00 | 0.00 |
South Asian | 0.0000524 | 0.0000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Functions both as NADH oxidoreductase and as regulator of apoptosis. In response to apoptotic stimuli, it is released from the mitochondrion intermembrane space into the cytosol and to the nucleus, where it functions as a proapoptotic factor in a caspase-independent pathway. In contrast, functions as an antiapoptotic factor in normal mitochondria via its NADH oxidoreductase activity. The soluble form (AIFsol) found in the nucleus induces 'parthanatos' i.e. caspase-independent fragmentation of chromosomal DNA. Interacts with EIF3G,and thereby inhibits the EIF3 machinery and protein synthesis, and activates casapse-7 to amplify apoptosis. Plays a critical role in caspase- independent, pyknotic cell death in hydrogen peroxide-exposed cells. Binds to DNA in a sequence-independent manner. {ECO:0000269|PubMed:17094969, ECO:0000269|PubMed:19418225, ECO:0000269|PubMed:20362274, ECO:0000269|PubMed:23217327}.;
- Disease
- DISEASE: Combined oxidative phosphorylation deficiency 6 (COXPD6) [MIM:300816]: A mitochondrial disease resulting in a neurodegenerative disorder characterized by psychomotor delay, hypotonia, areflexia, muscle weakness and wasting. Some patients manifest prenatal ventriculomegaly and severe postnatal encephalomyopathy. {ECO:0000269|PubMed:20362274, ECO:0000269|PubMed:22019070}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Cowchock syndrome (COWCK) [MIM:310490]: An X-linked recessive neuromuscular disorder characterized by early childhood onset of a slowly progressive axonal sensorimotor neuropathy associated in some patients with sensorineural deafness and cognitive impairment. {ECO:0000269|PubMed:23217327}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Deafness, X-linked, 5 (DFNX5) [MIM:300614]: A form of hearing loss characterized by absent or severely abnormal auditory brainstem response, abnormal middle ear reflexes, abnormal speech discrimination, loss of outer hair cell function, and cochlear nerve hypoplasia. DFNX5 patients manifest auditory neuropathy with childhood onset, associated with distal sensory impairment affecting the peripheral nervous system. {ECO:0000269|PubMed:25986071}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
- Pathway
- Necroptosis - Homo sapiens (human);Apoptosis - Homo sapiens (human);Apoptosis Modulation and Signaling;Nanomaterial induced apoptosis;Apoptosis Modulation by HSP70;RAGE;role of mitochondria in apoptotic signaling;opposing roles of aif in apoptosis and cell survival;ceramide signaling pathway;Ceramide signaling pathway
(Consensus)
Recessive Scores
- pRec
- 0.380
Intolerance Scores
- loftool
- 0.0837
- rvis_EVS
- -0.27
- rvis_percentile_EVS
- 34.6
Haploinsufficiency Scores
- pHI
- 0.325
- hipred
- Y
- hipred_score
- 0.729
- ghis
- 0.547
Essentials
- essential_gene_CRISPR
- E
- essential_gene_CRISPR2
- E
- essential_gene_gene_trap
- E
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.773
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Aifm1
- Phenotype
- integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); growth/size/body region phenotype; cellular phenotype; homeostasis/metabolism phenotype; muscle phenotype; vision/eye phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); embryo phenotype; behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan);
Gene ontology
- Biological process
- response to ischemia;apoptotic process;activation of cysteine-type endopeptidase activity involved in apoptotic process;chromosome condensation;positive regulation of apoptotic process;positive regulation of neuron apoptotic process;neuron apoptotic process;oxidation-reduction process;intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress;cellular response to hydrogen peroxide;cellular response to estradiol stimulus;cellular response to nitric oxide;cellular response to oxygen-glucose deprivation;response to L-glutamate;regulation of apoptotic DNA fragmentation;cellular response to aldosterone
- Cellular component
- nucleus;mitochondrion;mitochondrial inner membrane;mitochondrial intermembrane space;cytosol;perinuclear region of cytoplasm
- Molecular function
- DNA binding;protein binding;NAD(P)H oxidase activity;oxidoreductase activity, acting on NAD(P)H;protein dimerization activity;FAD binding